Most Undervalued Stocks Based on Predictive Analytics : Returns up to 62.19% in 1 Month

fundamentals Package Name: Fundamental - Low P/E Stocks
Recommended Positions: Short
Forecast Length: 1 Month (09/30/2018 - 10/30/2018)
I Know First Average: 24.63%

Read The Full Forecast

Most Undervalued Stocks

High Risk High Reward Stocks Based on Big Data: Returns up to 27.46% in 7 Days

Package Name: Risk-Conscious - Aggressive Stocks Forecast
Recommended Positions: Short
Forecast Length: 7 Days (10/17/2018 - 10/24/2018)
I Know First Average: 14.39%

Read The Full Forecast

High Risk High Reward Stocks

Machine Learning Stock Market Based on Algo Trading: Returns up to 37.43% in 7 Days

fundamentals Package Name: Fundamental - High PEG Stocks
Recommended Positions: Short
Forecast Length: 7 Days (09/28/2018 - 10/05/2018)
I Know First Average: 10.72%

Read The Full Forecast

Machine Learning Stock Market

Trend Prediction Algorithm Based on Machine Learning: Returns up to 44.17% in 7 Days

fundamentals Package Name: Fundamental - High PEG Stocks
Recommended Positions: Long
Forecast Length: 7 Days (08/30/2018 - 09/06/2018)
I Know First Average: 4.73%

Read The Full Forecast

Trend Prediction Algorithm

Bargain Stocks Based on Data Mining: Returns up to 175.95% in 1 Year

Package Name: Stocks Under 10 Dollars
Recommended Positions: Long
Forecast Length: 1 Year (05/16/2017 - 05/16/2018)
I Know First Average: 36.01%

Read The Full Forecast

Bargain Stocks

Stock Algorithms Based on Artificial Intelligence: Returns up to 160.61% in 1 Year

under 5 Package Name: Stocks Under 5 Dollars
Recommended Positions: Long
Forecast Length: 1 Year (05/10/2017 - 05/10/2018)
I Know First Average: 37.02%

Read The Full Forecast

Stock Algorithms

Quick Win by the Algorithm: Geron Corporation (NASDAQ: GERN) Treats Investors With Stock Up 24.71% In 3 Days

Quick Algorithm

“With the preliminary data from IMerge presented at ASH, we now have clinical data in three blood cancers, ET, MF and MDS, where imetelstat exhibits potential disease modifying activity by inhibiting the progenitor cells of the malignant clones that drive the underlying diseases”

– said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer.

(Image Source: www.troutaccess.com)

Geron Corporation (NASDAQ: GERN) operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the

Read More